Can elevated homocysteine with an MTHFR A1298C variant and macrocytic red cell indices reflect a one-carbon metabolism bottleneck?

Elevated homocysteine plus macrocytic red-cell indices in this 52-year-old man is compatible with impaired folate- or vitamin B12-dependent one-carbon metabolism. MTHFR A1298C is mechanistically relevant, but does not by itself establish either the cause of hyperhomocysteinemia or impaired clearance.

Clinical and biochemical interpretation

• Folate-derived 5-methyltetrahydrofolate and vitamin B12 are required to remethylate homocysteine to methionine, supporting S-adenosylmethionine (SAM) production and DNA synthesis. Impairment can therefore produce both elevated homocysteine and macrocytosis.
• A1298C modestly reduces MTHFR activity—reported residual activity is approximately 83% for heterozygotes and 61–68% for CC homozygotes—but studies do not consistently show elevated homocysteine, altered folate metabolites, or global DNA-methylation changes from this variant alone.
• The practical differential remains broader than genotype: assess vitamin B12, folate, methylmalonic acid when B12 status is uncertain, repeat homocysteine, renal and thyroid function, alcohol exposure, medications, malabsorption, reticulocytes, and peripheral smear. B12 deficiency often raises both methylmalonic acid and homocysteine; folate deficiency more typically raises homocysteine alone.

Mechanism and clearance relevance

• Reduced methyl-donor availability can decrease hepatic SAM, raise S-adenosylhomocysteine (SAH), and lower the SAM:SAH ratio, inhibiting SAM-dependent methyltransferases. Experimental inhibition of hepatic betaine--homocysteine methyltransferase reduced hepatocyte SAM by about 50%.
• The clearest clearance example is arsenic: AS3MT-mediated SAM-dependent methylation generates DMA, which is comparatively less toxic and rapidly urinary excreted. As3mt knockout mice have markedly slower whole-body arsenic elimination.
• This does not establish generalized impaired hepatic drug clearance. Although COMT and TPMT use SAM, direct evidence linking low hepatic SAM/SAH ratios to clinically meaningful drug pharmacokinetic changes is lacking.

Bottom line

• This pattern can reflect a one-carbon/methylation bottleneck and plausibly constrain selected methylation-dependent clearance pathways, especially arsenic metabolism; it should prompt evaluation for reversible B12 or folate deficiency and other causes of macrocytosis, not clearance or dosing assumptions based on A1298C alone.